Princeton, New Jersey12 days ago
D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.
We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.
At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals.
Oversee development of key regulatory content, including briefing documents, response packages, eCTD Module 2 summaries and overviews, protocols and protocol amendments, clinical study reports (CSRs), and responses to health authority questions.